The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
Open accessAbstract
BACKGROUND: A randomized phase 3 trial of the treatment of squamous-cell carcinoma of the head and neck compared induction chemotherapy with docetaxel plus cisplatin and fluorouracil (TPF) with cisplatin and fluorouracil (PF), followed by chemoradiotherapy. METHODS: We randomly assigned 501 patients (all of whom had stage III or IV disease with no distant metastases and tumors considered to be unresectable or were candidates for organ preservation) to receive either TPF or PF induction chemotherapy, followed by chemoradiotherapy with weekly carboplatin therapy and radiotherapy for 5 days per week. The primary end point was overall survival. RESULTS: With a minimum of 2 years of follow-up (> or =3 years for 69% of patients), significantly more patients survived in the TPF group than in the PF group (hazard ratio for death, 0.70; P=0.006). Estimates of overall survival at 3 years were 62% in the TPF group and 48% in the PF group; the median overall survival was 71 months and 30 months, respectively (P=0.006). There was better locoregional control in the TPF group than in the PF group (P=0.04), but the incidence of distant metastases in the two groups did not differ significantly (P=0.14). Rates of neutropenia and febrile neutropenia were higher in the TPF group; chemotherapy was more frequently delayed because of hematologic adverse events in the PF group. CONCLUSIONS: Patients with squamous-cell carcinoma of the head and neck who received docetaxel plus cisplatin and fluorouracil induction chemotherapy plus chemoradiotherapy had a significantly longer survival than did patients who received cisplatin and fluorouracil induction chemotherapy plus chemoradiotherapy. (ClinicalTrials.gov number, NCT00273546 [ClinicalTrials.gov].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Smigal, C., & Thun, M. J. (2006) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.56.2.106 · Cited by 5,314
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,115
Self-citationCooper, J. S., Pajak, T. F., Forastiere, A. A., Jacobs, J., Campbell, B. H., Saxman, S. B., Kish, J. A., Kim, H. E., Cmelak, A. J., Rotman, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032646 · Cited by 3,269
Self-citationBernier, J., Domenge, C., Ozsahin, M., Matuszewska, K., Lefèbvre, J.-L., Greiner, R. H., Giralt, J., Maingon, P., Rolland, F., Bolla, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032641 · Cited by 3,192
Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer
Forastiere, A. A., Goepfert, H., Maor, M., Pajak, T. F., Weber, R., Morrison, W., Glisson, B., Trotti, A., Ridge, J. A., Chao, C., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa031317 · Cited by 3,174
Pignon, J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)90011-0 · Cited by 2,543
Adelstein, D. J., Li, Y., Adams, G. L., Wagner, H., Kish, J. A., Ensley, J. F., Schuller, D. E., & Forastiere, A. A. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.008 · Cited by 1,748
Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer
Vermorken, J. B., Remenar, E., van Herpen, C., Gorlia, T., Mesia, R., Degardin, M., Stewart, J. S., Jelic, S., Betka, J., Preiss, J. H., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071028 · Cited by 1,719
American Joint Committee On Cancer (2010) · Springer eBooks · doi:10.1007/978-0-387-88443-1 · Cited by 1,386
Lefebvre, J.-L., Chevalier, D., Luboinski, B., Kirkpatrick, A., Collette, L., & Sahmoud, T. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.13.890 · Cited by 1,334
A Confidence Interval for the Median Survival Time
Brookmeyer, R., & Crowley, J. (1982) · Biometrics · doi:10.2307/2530286 · Cited by 914
Denis, F., Garaud, P., Bardet, E., Alfonsi, M., Sire, C., Germain, T., Bergerot, P., Rhein, B., Tortochaux, J., & Calais, G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.021 · Cited by 900
Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma
Domenge, C., Hill, C., Lefebvre, J. L., De Raucourt, D., Rhein, B., Wibault, P., Marandas, P., Coche-Dequeant, B., Stromboni-Luboinski, M., Sancho-Garnier, H., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1512 · Cited by 254
Carboplatin as a potentiator of radiation therapy
Douple, E. B., Richmond, R. C., O'Hara, J. A., & Coughlin, C. T. (1985) · Cancer Treatment Reviews · doi:10.1016/0305-7372(85)90026-x · Cited by 169
Chitapanarux, I., Lorvidhaya, V., Kamnerdsupaphon, P., Sumitsawan, Y., Tharavichitkul, E., Sukthomya, V., & Ford, J. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.03.022 · Cited by 153
Head and Neck Cancer: Recent Advances and New Standards of Care
Forastiere, A. A., Trotti, A., Pfister, D. G., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.1464 · Cited by 108
Schrijvers, D. M., van Herpen, C., Kerger, J. N., Joosens, E., Laer, C. V., Awada, A. H., den Weyngaert, D. V., Nguyen, H. C. B., Bouder, C. L., Castelijns, J. A., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh145 · Cited by 85
Posner, M. R., Haddad, R. I., Wirth, L. J., Norris, C. M., Goguen, L. A., Mahadevan, A., Sullivan, C. A., & Tishler, R. B. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.09.007 · Cited by 82
Self-citation
Cited by
Head and neck squamous cell carcinoma
Johnson, D. E., Burtness, B., Leemans, C. R., Lui, V. W. Y., Bauman, J. E., & Grandis, J. R. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00224-3 · Cited by 4,067
Pignon, J.-P., Maître, A. L., Maillard, E., & Bourhis, J. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2009.04.014 · Cited by 3,069
Argiris, A., Karamouzis, M. V., Raben, D., & Ferris, R. L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60728-x · Cited by 2,224
Chow, L. Q. M. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1715715 · Cited by 2,075
Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer
Vermorken, J. B., Remenar, E., van Herpen, C., Gorlia, T., Mesia, R., Degardin, M., Stewart, J. S., Jelic, S., Betka, J., Preiss, J. H., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071028 · Cited by 1,719
Metadata
- Authors
- Posner, M. R., Hershock, D. M., Blajman, C. R., Mickiewicz, E., Winquist, E., Gorbounova, V., Tjulandin, S., Shin, D. M., Cullen, K., Ervin, T. J., Murphy, B. A., Raez, L. E., Cohen, R. B., Spaulding, M., Tishler, R. B., Roth, B., Viroglio, R. D. C., Venkatesan, V., Romanov, I., Agarwala, S., Harter, K. W., Dugan, M., Cmelak, A., Markoe, A. M., Read, P. W., Steinbrenner, L., Colevas, A. D., Norris, C. M., & Haddad, R. I.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-10-25
- Volume
- 357
- Issue
- 17
- Pages
- 1705-1715
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141592118
- Cited by
- 1,705
- References
- 18
- FWCI
- 97.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.